Logan Lutton

Here’s what you missed this week on Managed Healthcare Executive.

Patient follow-up 10 years after hormone replacement therapy treatment revealed there were no long-term negative cognitive effects.

Produced in Chinese hamster ovary cells, Ziihera (zanidatamab-hrii) is the first HER2-targeted bispecific antibody treatment for patients with previously treated, unresectable or metastatic biliary tract cancer.

The FDA has approved UCB's Bimzelx for moderate-to-severe hidradenitis suppurativa, offering a new treatment option for this painful autoimmune skin disease.

Medicare fraud costs Americans about $60 billion each year and healthcare plans are stepping in spread awareness and stop criminals.

Relapsed or refractory acute leukemia with a KMT2A translocation currently has an overall survival rate of less than one year when treated with frontline therapies.

Researchers are currently enrolling participants to test the effectiveness of a rectal douche containing the antiretroviral drug tenofovir in a study that is expected to finish in January 2026.

Breast cancer treatment settings prove to be a good opportunity to talk about financial toxicity. These conversations can also happen in generalized healthcare, according to Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.

Current financial screening procedures in the United States may need to change, according to recent research done by Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University.

Here’s what you missed this week on Managed Healthcare Executive.

Laila Gharzai, M.D., LLM, from the Department of Radiation Oncology at Northwestern University explains the concept of financial toxicity and how it affects breast cancer treatment outcomes.

Canadian study reveals that women who undergo early menopause are less at risk for asthma than women who experience menopause late.

A new study found that iron supplements are safe for children with HIV in Uganda, as they improve hemoglobin levels without increasing malaria risk.

A recent study reveals that nearly 20% of United States physicians treating HIV patients plan to leave or reduce their caseload within five years, even as demand for HIV care is expected to rise.

If approved, donidalorsen would be a first-in-class RNA-targeted medicine for hereditary angioedema. The agency’s goal date is August 21, 2025.

Here’s what you missed this week on Managed Healthcare Executive.

Type 1 diabetes is a relentless disease, according to David Maahs, M.D., M.A., Ph.D., from Stanford University.

The rising popularity of the continuous glucose monitor, which is not the same as an insulin pump, has been a huge advance in type 1 diabetes treatment, according to David Maahs, M.D., M.A., Ph.D., from Stanford University.

David Maahs, M.D., M.A., Ph.D., explains why teamwork is the most important part of the 4T diabetes management program.

David Maahs, M.D., M.A., Ph.D., explains the role that teamwork, targets, technology and tight control plays in type 1 diabetes management and why it’s best to intervene right after diagnosis.

Scemblix (asciminib) is a new first-line option for adults with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP).

Prademagene zamikeracel (pz-cel) could be a new treatment for rare genetic disease recessive dystrophic epidermolysis bullosa (RDEB).

The effects of breast cancer can remain long after the disease has left the body, serving as a traumatic daily reminder.

Here’s what you missed this week on Managed Healthcare Executive.

Popular menopause prescriptions such as Estradiol, Dotti, Premarin and Veozah will be available for cheaper using a GoodRx coupon.

This week’s approval expands Seldardsi indications to treat adults with Crohn’s disease and ulcerative colitis.

Stephanie Graff, M.D., FACP, FASCO, director of breast oncology at the Lifespan Cancer Institute and author of Investigating the Salience of Clinical Meaningfulness and Clinically Meaningful Outcomes in Metastatic Breast Cancer Care Delivery, shares the reasons why she chose to study metastatic breast cancer patients.

There is a need for strict policies regarding the use of AI in the managed care space, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.

Health plans and PBMs are using AI to aggregate data, summarize information and enhance their formulary decision-making processes, according to Douglas S. Burgoyne, Pharm.D., MBA, FAMCP, adjunct associate professor at the University of Utah College of Pharmacy.

Technology can help address the complexities of specialty medications by automating processes and enabling proactive interventions to ensure patients stay on their critical therapies, according to Kristen Whelchel, Pharm.D., CSP, Research and Patient Care Improvement Pharmacist with Vanderbilt Specialty Pharmacy's Department of Health Outcomes and Research.